Topical NSAID – Combines 2% diclofenac sodium with the transdermal drug carrier dimethyl sulfoxide (DMSO)
- Treating the pain of osteoarthritis of the knee
- Low systemic exposure to minimize side effects
- First twice per day dosing topical NSAID in the U.S.
- Metered dose dispenser
- Marketed in the U.S. by Horizon Pharma plc – January 2015
- Patents issued and allowed in seventeen countries (ex-U.S.) and pending in six countries with the latest expiring 2027
- U.S.: www.pennsaid.com